Uncategorized
Exelixis’ Cabometyx successor fails primary endpoint in colorectal cancer trial amid FDA review
Exelixis’ next franchise in a drug, zanzalintinib, has hit a clinical setback, although at least two groups of analysts suggested that an FDA approval is still on the table.